Corcept Therapeutics (CORT) — insider trading
Health Care · NASDAQ
Corcept Therapeutics (CORT) has 206 reported SEC Form 4 insider transactions in our data, including 41 open-market sales among the most recent 100 (latest 2026-10-02).
Recent Form 4 transactions
Showing the 100 most recent of 206 recorded transactions. See all on SEC EDGAR →
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Vieira Roberto Wandenkolk | Officer (President, Oncology) | Option exercise / conversion (derivative) | 8,333 | — | $0 | Form 4 |
| 2026-10-02 | Vieira Roberto Wandenkolk | Officer (President, Oncology) | Open-market sale | 5,147 | $116.59 | $600.1K | Form 4 |
| 2026-10-02 | Vieira Roberto Wandenkolk | Officer (President, Oncology) | Open-market sale | 2,086 | $115.73 | $241.4K | Form 4 |
| 2026-10-02 | Vieira Roberto Wandenkolk | Officer (President, Oncology) | Open-market sale | 1,100 | $114.52 | $126.0K | Form 4 |
| 2026-10-02 | Vieira Roberto Wandenkolk | Officer (President, Oncology) | Option exercise / conversion | 8,333 | $21.63 | $180.2K | Form 4 |
| 2026-10-02 | Lyon Joseph Douglas | Officer (See Remarks) | Option exercise / conversion (derivative) | 5,833 | — | $0 | Form 4 |
| 2026-10-02 | Lyon Joseph Douglas | Officer (See Remarks) | Option exercise / conversion (derivative) | 3,357 | — | $0 | Form 4 |
| 2026-10-02 | Lyon Joseph Douglas | Officer (See Remarks) | Open-market sale | 4,744 | $116.54 | $552.9K | Form 4 |
| 2026-10-02 | Lyon Joseph Douglas | Officer (See Remarks) | Open-market sale | 4,446 | $115.70 | $514.4K | Form 4 |
| 2026-10-02 | Lyon Joseph Douglas | Officer (See Remarks) | Option exercise / conversion | 5,833 | $19.26 | $112.3K | Form 4 |
| 2026-10-02 | Lyon Joseph Douglas | Officer (See Remarks) | Option exercise / conversion | 3,357 | $13.56 | $45.5K | Form 4 |
| 2026-10-02 | Maduck Sean | Officer (See Remarks) | Option exercise / conversion (derivative) | 24,587 | — | $0 | Form 4 |
| 2026-10-02 | Maduck Sean | Officer (See Remarks) | Open-market sale | 8,744 | $116.55 | $1.02M | Form 4 |
| 2026-10-02 | Maduck Sean | Officer (See Remarks) | Open-market sale | 15,843 | $116.12 | $1.84M | Form 4 |
| 2026-10-02 | Maduck Sean | Officer (See Remarks) | Option exercise / conversion | 24,587 | $8.27 | $203.3K | Form 4 |
| 2026-10-01 | Lyon Joseph Douglas | Officer (See Remarks) | Option exercise / conversion (derivative) | 810 | — | $0 | Form 4 |
| 2026-10-01 | Lyon Joseph Douglas | Officer (See Remarks) | Open-market sale | 810 | $115.40 | $93.5K | Form 4 |
| 2026-10-01 | Lyon Joseph Douglas | Officer (See Remarks) | Option exercise / conversion | 810 | $13.56 | $11.0K | Form 4 |
| 2026-10-01 | Maduck Sean | Officer (See Remarks) | Option exercise / conversion (derivative) | 413 | — | $0 | Form 4 |
| 2026-10-01 | Maduck Sean | Officer (See Remarks) | Open-market sale | 413 | $115.54 | $47.7K | Form 4 |
| 2026-10-01 | Maduck Sean | Officer (See Remarks) | Option exercise / conversion | 413 | $8.27 | $3.4K | Form 4 |
| 2026-10-01 | Gunn Justin Frederick | Officer (See Remarks) | Grant / award / vesting (derivative) | 100,000 | — | $0 | Form 4 |
| 2026-09-24 | Robb Gary Charles | Officer (Chief Business Officer) | Bona fide gift | 5,000 | — | $0 | Form 4 |
| 2026-09-24 | Robb Gary Charles | Officer (Chief Business Officer) | Bona fide gift | 5,000 | — | $0 | Form 4 |
| 2026-09-24 | Robb Gary Charles | Officer (Chief Business Officer) | Bona fide gift | 17,100 | — | $0 | Form 4 |
| 2026-09-17 | Robb Gary Charles | Officer (Chief Business Officer) | Option exercise / conversion (derivative) | 17,493 | — | $0 | Form 4 |
| 2026-09-17 | Robb Gary Charles | Officer (Chief Business Officer) | Option exercise / conversion | 17,493 | $8.27 | $144.7K | Form 4 |
| 2026-09-16 | Vieira Roberto Wandenkolk | Officer (President, Oncology) | Open-market sale | 296 | $100.82 | $29.8K | Form 4 |
| 2026-09-15 | WILSON JAMES N | Director | Open-market sale | 2,800 | $111.70 | $312.8K | Form 4 |
| 2026-09-15 | WILSON JAMES N | Director | Open-market sale | 400 | $110.84 | $44.3K | Form 4 |
| 2026-09-15 | WILSON JAMES N | Director | Open-market sale | 6,800 | $110.27 | $749.8K | Form 4 |
| 2026-09-14 | Lyon Joseph Douglas | Officer (See Remarks) | Option exercise / conversion (derivative) | 7,404 | — | $0 | Form 4 |
| 2026-09-14 | Lyon Joseph Douglas | Officer (See Remarks) | Option exercise / conversion (derivative) | 2,596 | — | $0 | Form 4 |
| 2026-09-14 | Lyon Joseph Douglas | Officer (See Remarks) | Open-market sale | 2,188 | $114.12 | $249.7K | Form 4 |
| 2026-09-14 | Lyon Joseph Douglas | Officer (See Remarks) | Open-market sale | 7,812 | $113.32 | $885.3K | Form 4 |
| 2026-09-14 | Lyon Joseph Douglas | Officer (See Remarks) | Option exercise / conversion | 7,404 | $13.56 | $100.4K | Form 4 |
| 2026-09-14 | Lyon Joseph Douglas | Officer (See Remarks) | Option exercise / conversion | 2,596 | $11.35 | $29.5K | Form 4 |
| 2026-09-02 | Maduck Sean | Officer (See Remarks) | Shares withheld for taxes / exercise cost | 117 | $113.38 | $13.3K | Form 4 |
| 2026-09-02 | Mokari Atabak | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 102 | $113.38 | $11.6K | Form 4 |
| 2026-09-02 | Robb Gary Charles | Officer (Chief Business Officer) | Shares withheld for taxes / exercise cost | 91 | $113.38 | $10.3K | Form 4 |
| 2026-09-02 | Vieira Roberto Wandenkolk | Officer (President, Oncology) | Option exercise / conversion (derivative) | 58,333 | — | $0 | Form 4 |
| 2026-09-02 | Vieira Roberto Wandenkolk | Officer (President, Oncology) | Open-market sale | 1,225 | $115.44 | $141.4K | Form 4 |
| 2026-09-02 | Vieira Roberto Wandenkolk | Officer (President, Oncology) | Open-market sale | 5,621 | $114.58 | $644.0K | Form 4 |
| 2026-09-02 | Vieira Roberto Wandenkolk | Officer (President, Oncology) | Open-market sale | 1,606 | $113.72 | $182.6K | Form 4 |
| 2026-09-02 | Vieira Roberto Wandenkolk | Officer (President, Oncology) | Open-market sale | 974 | $112.40 | $109.5K | Form 4 |
| 2026-09-02 | Vieira Roberto Wandenkolk | Officer (President, Oncology) | Open-market sale | 1,537 | $111.37 | $171.2K | Form 4 |
| 2026-09-02 | Vieira Roberto Wandenkolk | Officer (President, Oncology) | Open-market sale | 23,770 | $110.70 | $2.63M | Form 4 |
| 2026-09-02 | Vieira Roberto Wandenkolk | Officer (President, Oncology) | Open-market sale | 23,600 | $109.35 | $2.58M | Form 4 |
| 2026-09-02 | Vieira Roberto Wandenkolk | Officer (President, Oncology) | Option exercise / conversion | 58,333 | $21.63 | $1.26M | Form 4 |
| 2026-09-02 | Vieira Roberto Wandenkolk | Officer (President, Oncology) | Shares withheld for taxes / exercise cost | 102 | $113.38 | $11.6K | Form 4 |
| 2026-09-02 | Lyon Joseph Douglas | Officer (See Remarks) | Shares withheld for taxes / exercise cost | 72 | $113.38 | $8.2K | Form 4 |
| 2026-09-01 | Guyer William | Officer (Chief Development Officer) | Grant / award / vesting | 164 | — | $0 | Form 4 |
| 2026-09-01 | Guyer William | Officer (Chief Development Officer) | Grant / award / vesting | 164 | $113.38 | $18.6K | Form 4 |
| 2026-09-01 | Maduck Sean | Officer (See Remarks) | Option exercise / conversion (derivative) | 25,000 | — | $0 | Form 4 |
| 2026-09-01 | Maduck Sean | Officer (See Remarks) | Grant / award / vesting | 150 | — | $0 | Form 4 |
| 2026-09-01 | Maduck Sean | Officer (See Remarks) | Grant / award / vesting | 150 | $113.38 | $17.0K | Form 4 |
| 2026-09-01 | Maduck Sean | Officer (See Remarks) | Open-market sale | 2,281 | $115.61 | $263.7K | Form 4 |
| 2026-09-01 | Maduck Sean | Officer (See Remarks) | Open-market sale | 10,989 | $114.71 | $1.26M | Form 4 |
| 2026-09-01 | Maduck Sean | Officer (See Remarks) | Open-market sale | 11,730 | $113.94 | $1.34M | Form 4 |
| 2026-09-01 | Maduck Sean | Officer (See Remarks) | Option exercise / conversion | 25,000 | $8.27 | $206.8K | Form 4 |
| 2026-09-01 | Mokari Atabak | Officer (Chief Financial Officer) | Grant / award / vesting | 138 | — | $0 | Form 4 |
| 2026-09-01 | Mokari Atabak | Officer (Chief Financial Officer) | Grant / award / vesting | 138 | $113.38 | $15.6K | Form 4 |
| 2026-09-01 | Robb Gary Charles | Officer (Chief Business Officer) | Grant / award / vesting | 164 | — | $0 | Form 4 |
| 2026-09-01 | Robb Gary Charles | Officer (Chief Business Officer) | Grant / award / vesting | 164 | $113.38 | $18.6K | Form 4 |
| 2026-09-01 | Vieira Roberto Wandenkolk | Officer (President, Oncology) | Grant / award / vesting | 138 | — | $0 | Form 4 |
| 2026-09-01 | Vieira Roberto Wandenkolk | Officer (President, Oncology) | Grant / award / vesting | 138 | $113.38 | $15.6K | Form 4 |
| 2026-09-01 | Lyon Joseph Douglas | Officer (See Remarks) | Grant / award / vesting | 130 | — | $0 | Form 4 |
| 2026-09-01 | Lyon Joseph Douglas | Officer (See Remarks) | Grant / award / vesting | 130 | $113.38 | $14.7K | Form 4 |
| 2026-08-26 | Park Kimberly | Director | Option exercise / conversion (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-08-26 | Park Kimberly | Director | Open-market sale | 26,685 | $122.55 | $3.27M | Form 4 |
| 2026-08-26 | Park Kimberly | Director | Shares withheld for taxes / exercise cost | 3,315 | $122.09 | $404.7K | Form 4 |
| 2026-08-26 | Park Kimberly | Director | Option exercise / conversion | 30,000 | $13.49 | $404.7K | Form 4 |
| 2026-08-25 | Maduck Sean | Officer (See Remarks) | Option exercise / conversion (derivative) | 30,955 | — | $0 | Form 4 |
| 2026-08-25 | Maduck Sean | Officer (See Remarks) | Open-market sale | 5,870 | $126.06 | $740.0K | Form 4 |
| 2026-08-25 | Maduck Sean | Officer (See Remarks) | Open-market sale | 25,085 | $125.47 | $3.15M | Form 4 |
| 2026-08-25 | Maduck Sean | Officer (See Remarks) | Option exercise / conversion | 30,955 | $11.35 | $351.3K | Form 4 |
| 2026-08-18 | MAHONEY DAVID L | Director | Open-market sale | 400 | $119.64 | $47.9K | Form 4 |
| 2026-08-18 | MAHONEY DAVID L | Director | Open-market sale | 7,055 | $118.88 | $838.7K | Form 4 |
| 2026-08-18 | MAHONEY DAVID L | Director | Open-market sale | 91,167 | $118.24 | $10.78M | Form 4 |
| 2026-08-18 | MAHONEY DAVID L | Director | Open-market sale | 4,984 | $117.47 | $585.5K | Form 4 |
| 2026-08-17 | Robb Gary Charles | Officer (Chief Business Officer) | Open-market sale | 10,000 | $116.26 | $1.16M | Form 4 |
| 2026-08-17 | Robb Gary Charles | Officer (Chief Business Officer) | Bona fide gift | 125 | — | $0 | Form 4 |
| 2026-08-14 | WILSON JAMES N | Director | Open-market sale | 2,279 | $112.64 | $256.7K | Form 4 |
| 2026-08-14 | WILSON JAMES N | Director | Open-market sale | 4,668 | $111.44 | $520.2K | Form 4 |
| 2026-08-14 | WILSON JAMES N | Director | Open-market sale | 3,053 | $110.49 | $337.3K | Form 4 |
| 2026-08-14 | Maduck Sean | Officer (See Remarks) | Option exercise / conversion (derivative) | 3,664 | — | $0 | Form 4 |
| 2026-08-14 | Maduck Sean | Officer (See Remarks) | Open-market sale | 3,664 | $114.49 | $419.5K | Form 4 |
| 2026-08-14 | Maduck Sean | Officer (See Remarks) | Option exercise / conversion | 3,664 | $8.27 | $30.3K | Form 4 |
| 2026-08-12 | Robb Gary Charles | Officer (Chief Business Officer) | Bona fide gift | 3,000 | — | $0 | Form 4 |
| 2026-08-12 | Robb Gary Charles | Officer (Chief Business Officer) | Bona fide gift | 3,000 | — | $0 | Form 4 |
| 2026-08-12 | Robb Gary Charles | Officer (Chief Business Officer) | Bona fide gift | 11,530 | — | $0 | Form 4 |
| 2026-08-10 | Guyer William | Officer (Chief Development Officer) | Option exercise / conversion (derivative) | 16,300 | — | $0 | Form 4 |
| 2026-08-10 | Guyer William | Officer (Chief Development Officer) | Open-market sale | 4,770 | $114.04 | $544.0K | Form 4 |
| 2026-08-10 | Guyer William | Officer (Chief Development Officer) | Open-market sale | 11,530 | $113.18 | $1.30M | Form 4 |
| 2026-08-10 | Guyer William | Officer (Chief Development Officer) | Option exercise / conversion | 16,300 | $21.65 | $352.9K | Form 4 |
| 2026-08-10 | Maduck Sean | Officer (See Remarks) | Option exercise / conversion (derivative) | 1,031 | — | $0 | Form 4 |
| 2026-08-10 | Maduck Sean | Officer (See Remarks) | Open-market sale | 1,031 | $114.52 | $118.1K | Form 4 |
| 2026-08-10 | Maduck Sean | Officer (See Remarks) | Option exercise / conversion | 1,031 | $8.27 | $8.5K | Form 4 |
| 2026-08-04 | Guyer William | Officer (Chief Development Officer) | Option exercise / conversion (derivative) | 3,700 | — | $0 | Form 4 |
| 2026-08-04 | Guyer William | Officer (Chief Development Officer) | Open-market sale | 3,700 | $113.12 | $418.6K | Form 4 |
Ask the chat about CORT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Corcept Therapeutics (CORT).
Last updated 2026-10-02 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.